-Severely penalized, INGN reached the low point ultimately traced.
-A large part of your penalty was due to numerous deficit balance sheets and, mainly, due to the increase in the American interest rate. We know that companies that depend on third-party capital to finance themselves are the ones that suffer the most.
-In the monthly chart, oddly enough, the...
It seems to me that the final destination of the asset in question will be its most remote bottom, at $13.12.
This asset scares me. The bears simply ruined this cute little bunny!
Or will he be a mouse given his never encouraging financial statements?
-Do your analysis and good business.
-Be Conscious, If You Buy, Use Stop!
-See below for other reviews!
The Inogen Inc. chart shows that it takes much longer to reach a Peak new All-Time High. However, a Topping Formation or Business Bear Downtrend occurs much faster. There is triple or quadruple the points profit in half the time when selling short a stock as compared to buying it going long in the market. This stock is now at a support level and is no longer a...
So today i have found NASDAQ:INGN for a fade (short) trade, if you look at the 5 min chart you will see that we are under the VWAP, and the MA's with a big window to fade, i will trade it as soon as it breaks the USD64.00 level, with a window all the way to USD60.00, my stop will be 10 cents above the VWAP, remember that i only trade short bias and i am looking...
INGN is heading in the right direction and looks like the put will expire worthless... we could be setting up for a head-and-shoulders on the daily. if we pull back into the purple ellipse, i'll look to pick up some calls
1.) Average age of consumers are 75+, only 10% of its sales come from medicare. <---- UNACCEPTABLE
2.) WRONG INFO GIVEN BY RESELLERS TO CUSTOMERS.
Per Citron:
Citron estimates that Inogen sells about 90% of its POC units vs. only renting about 10% through Medicare. Assuming 40% of POC units were rented through Medicare, Inogen’s revenue would decline by about...
At this point, I feel sorry for whoever's shorting this. Recorded $97 million on revenues this past Q2; +68% 200SMA, +24% 50SMA, +12% 20SMA, and backed by Medicare. Having worked in a hospital for so long and witnessed so many patients who will probably be in O2 the rest of their life, I can't believe that I ignored this company a few months ago. Who wants to...
Inogen is increasing its full year 2018 total revenue guidance range to $345 to $355 million, up from $340 to $350 million, representing growth of 38.3% to 42.3% versus 2017 full year results. The Company still expects direct-to-consumer sales to be its fastest growing channel, domestic business-to-business sales to have a significant growth rate, and...
